Creation of "Our Wellness Future"

Mission

The mission of TMS is to enhance human wellness through new medical discoveries. To achieve our mission, TMS works to identify and develop unique potential drug candidates from the academic realm with the aim of introducing these products into the market as quickly as possible. Ultimately, our goal is to help people suffering from a variety of diseases to recover their normal health and to improve their quality of life.

News and Events

2020.11.16: TMS announces completion of patient enrollment for TMS-007 acute ischemic stroke Phase IIa clinical study

2020.02.28: TMS Co., Ltd. Successfully Closes a Finance Round

2019.11.29: Enrollment of the second cohort in TMS-007 Phase II clinical trial was completed

2019.11.25: Method of use patent of SMTP compounds for ischemic damage was issued in US

2018.12.03: TMS appoints pharmaceutical executive Steve Engen as new Board member

2018.06.07: TMS signs Option Agreement with Biogen

2015.12.22: Our program entitled "Clinical development of TMS-007 as a novel stroke drug" has been granted a fund from The New Energy and Industrial Technology Development Organization (NEDO).

2015.11.16: We completed the phase l clinical trial of TMS-007 in October 2015.

2015.06.09: The investigation entitled "Nonclinical and clinical development of TMS-007, a member of the anti-inflammatory small-molecule thrombolytic SMTPs" is to be presented on the 2015 Congress of the International Society on Thrombosis and Haemostasis (ISTH 2015) (Abstracts p.698, No. PO528-TUE).

2015.04.13: Our presentation entitled "Nonclinical and clinical development of SMTP as a novel stroke drug" has been selected as the "Topics prizes" by the Committee of 2015 Annual Conference of Japan Society for Bioscience, Biotechnology and Agrochemistry.

2015.03.24: The investigation entitled "TMS-007, a novel anti-inflammatory thrombolytic in the family of the SMTP plasminogen modulators that suppresses hemorrhagic transformation, revolutionizes ischemic stroke" is to be presented on the SPC symposium of the 37th Congress of the Japanese Society on Thrombosis and Hemostasis.

2015.03.24: The investigation entitled "Nonclinical and clinical development of SMTP as a novel stroke drug" is to be presented on the 2015 Annual Conference of Japan Society for Bioscience, Biotechnology and Agrochemistry.

2015.03.24: Our collaborative investigation entitled "Soluble epoxide hydrolase as an anti-inflammatory target of the thrombolytic stroke drug SMTP-7." has been published in the Journal of Biological Chemistry 289: 35826–35838 (2014).

2015.03.24: Our collaborative investigation entitled "SMTP-7, a novel small-molecule thrombolytic for ischemic stroke: a study in rodents and primates." has been published in the Journal of Cerebral Blood Flow & Metabolism 34: 235–241 (2014).

2014.12.08: The phase l clinical trial of TMS-007 started in Japan in August 2014.

2011.10.24: Our program entitled "The development of a novel small molecule of microbial origin as a therapeutic agent that treat ischemic stroke" has been granted a fund from The Japan Science and Technology Agency.

2011.06.27: Website update.